The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Prophylactic Lactobacillus GG Reduces Antibiotic-Associated Diarrhea in Children With Respiratory Infections: A Randomized Study
Abstract
Objectives.: Antimicrobial treatment may disturb the colonization resistance of gastrointestinal microflora, which may induce clinical symptoms, most commonly diarrhea. The severity of antibiotic-associated diarrhea may range from a brief, self-limiting disease to devastating diarrhea with electrolyte disturbances, dehydration, crampy abdominal pain, pseudomembranous colitis, toxic megacolon, or even death. The incidence of diarrhea in children receiving a single antimicrobial treatment is unclear. In addition to more critical use of antimicrobials, adjunctive preventive measures to antibiotic-associated diarrhea are needed. The objective of this study was to evaluate the incidence of diarrhea after antimicrobial treatment in children with no history of antimicrobial use during the previous 3 months. Another aim of this study was to assess the preventive potential of Lactobacillus rhamnosus GG (Lactobacillus GG; American Type Culture Collection 53103), a probiotic strain with a documented safety record and a therapeutic effect in viral gastroenteritis on antibiotic-associated diarrhea. Methods.: Oral antimicrobial agents were prescribed for the treatment of acute respiratory infections at the clinics of the Health Care Center of the City of Tampere or Tampere University Hospital, Finland, to 167 patients who were invited to participate in the study. Of the patients, 48 were lost to follow-up; therefore, the final study population consisted of 119 children from 2 weeks to 12.8 years of age (mean: 4.5 years). All study subjects met the inclusion criteria: they had not received any antimicrobial medication during the previous 3 months, they did not suffer from gastrointestinal disorders, and they did not need intravenous antimicrobial treatment. The patients were randomized to receive placebo or 2 × 1010 colony-forming units of Lactobacillus GG in capsules given twice daily during the antimicrobial treatment. Lactobacillus GG and placebo capsules were indistinguishable in appearance and taste. The parents kept a daily symptom diary and recorded stool frequency and consistency at home for 3 months. Diarrhea was defined as at least three watery or loose stools per day for a minimum of 2 consecutive days. In the case of diarrhea, viral (adenovirus, rotavirus, calicivirus and astrovirus) and bacterial (Salmonella, Shigella, Yersinia, Campylobacter, Clostridium difficile, Staphylococcus aureus, and yeasts) analyses were studied in fecal samples. The metabolic activity of the gut microflora was assessed by analysis of fecal urease, β-glucosidase, and β-glucuronidase activities. The primary outcome measure was diarrhea during the first 2 weeks after the beginning of the antimicrobial treatment, because this period most likely reflects the effects of antimicrobial use. Secondary outcome measures were the activities of fecal urease, β-glucuronidase, and β-glucosidase. Results.: On the entire follow-up, 80% of any gastrointestinal symptoms were reported during the first 2 weeks after the beginning of the antimicrobial treatment. The incidence of diarrhea was 5% in the Lactobacillus GG group and 16% in the placebo group within 2 weeks of antimicrobial therapy (χ2 = 3.82). The treatment effect (95% confidence interval) of Lactobacillus GG was −11% (−21%–0%). In diarrheal episodes, the viral and bacterial analyses were positive for Clostridium difficile in 2 cases and for Norwalk-like calicivirus in 3 cases. The age of the patients with diarrhea was between 3 months and 5 years in 75% of cases in both groups. The severity of diarrhea was comparable in the study groups, as evidenced by similar stool frequency (mean: 5 per day; range: 3–6) and the duration of diarrhea (mean: 4 days; range: 2–8). The activities of fecal urease and β-glucuronidase, but not β-glucosidase, changed significantly after the beginning of the antimicrobial treatment in the Lactobacillus GG group and in the placebo group alike. The decrease in urease and β-glucuronidase activities was reversible in patients with no diarrhea, but in patients with diarrhea, the modifications in gut microflora were more profound and prolonged. The activities of the three enzymes were normalized within 3 weeks, evidenced by stable enzyme activities in samples collected 3 weeks, 1 month, and 3 months after the beginning of the antimicrobial treatment, compared with those obtained before treatment. Discussion.: In the present study, after a single antimicrobial treatment, the incidence of diarrhea was 16%. The higher incidence of antibiotic-associated diarrhea in previous reports may be attributable to a recent antimicrobial therapy that disturbs intestinal flora and exposes to complications. Also, in the present study, changes in the metabolic activity of the intestinal flora were observed, evidenced by a transient decline in fecal enzyme activities. Different probiotic preparations, including lactobacilli, are recommended frequently to prevent antibiotic-associated diarrhea. Although probiotics have been shown to be efficient in the prevention and the treatment of viral gastroenteritis, their usefulness during antimicrobial therapy in children has not been elucidated before. We observed that the administration of Lactobacillus GG to children receiving antimicrobial therapy for respiratory infection reduced the incidence of antibiotic-associated diarrhea to one third. The beneficial effect may be mediated by a number of functions of probiotics, ie, production of antimicrobial substances, local competition of adhesion receptors and nutrients, and stimulation of intestinal antigen specific and nonspecific immune responses. Conclusion.: A probiotic strain, Lactobacillus GG, is effective in the prevention of diarrhea in children receiving antimicrobial treatment to respiratory infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saavedra, J. M., Bauman, N. A., Perman, J. A., Yolken, R. H., Saavedra, J. M., Bauman, N. A., & Oung, I. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91708-6 · Cited by 970
Fuller, R. (1991) · Gut · doi:10.1136/gut.32.4.439 · Cited by 862
Kaila, M., Isolauri, E., Soppi, E., Virtanen, E., Laine, S., & Arvilommi, H. (1992) · Pediatric Research · doi:10.1203/00006450-199208000-00002 · Cited by 700
Self-citationIsolauri, E., Juntunen, M., Rautanen, T., Sillanaukee, P., & Koivula, T. (1991) · PubMed · Cited by 684
Self-citationSUCCESSFUL TREATMENT OF RELAPSING CLOSTRIDIUM DIFFICILE COLITIS WITH LACTOBACILLUS GG
Gorbach, S., Chang, T.-W., & Goldin, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92646-8 · Cited by 464
Antibiotic-Associated Diarrhea
Bartlett, J. G. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.4.573 · Cited by 414
(1976) · Food and Cosmetics Toxicology · doi:10.1016/s0015-6264(76)80265-9 · Cited by 382
Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo.
McFarland, L. V., Surawicz, C. M., Greenberg, R. N., Elmer, G. W., Moyer, K. A., Melcher, S. A., Bowen, K., & Cox, J. L. (1995) · PubMed · Cited by 338
Are antibiotics indicated as initial treatment for children with acute otitis media? A meta-analysis
Del Mar, C. B., Glasziou Paul, P., & Hayem, M. (1997) · BMJ · doi:10.1136/bmj.314.7093.1526 · Cited by 302
Antimicrobials for acute otitis media? a review from the international primary care network: Table 1
Froom, J., Culpepper, L., Jacobs, M., DeMelker, R. A., Green, L. A., van Buchem, L., Grob, P., & Heeren, T. (1997) · BMJ · doi:10.1136/bmj.315.7100.98 · Cited by 196
(2003) · Reviews in Food and Nutrition Toxicity · doi:10.1201/9780203634523-16 · Cited by 172
Recovery of Lactobacillus rhamnosus GG from human colonic biopsies
Alander, M., Korpela, R., Saxelin, M., Vilpponen‐Salmela, T., Mattila‐Sandholm, T., & Von Wright, A. (1997) · Letters in Applied Microbiology · doi:10.1046/j.1472-765x.1997.00140.x · Cited by 170
Mitchell, D. K., Monroe, S. S., Jiang, X., et al. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/172.6.1437 · Cited by 155
Hoberman, A., Paradise, J. L., BURCH, D. J., VALINSKI, W. A., HEDRICK, J. A., Aronovitz, G. H., Drehobl, M., & ROGERS, J. M. (1997) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199705000-00002 · Cited by 126
Recurrent wheezy bronchitis and viral respiratory infections.
Mertsola, J., Ziegler, T. T., Ruuskanen, O., Vanto, T., Koivikko, A., & Halonen, P. E. (1991) · Archives of Disease in Childhood · doi:10.1136/adc.66.1.124 · Cited by 123
Dose Response Colonisation of Faeces after Oral Administration ofLactobacillus caseiStrain GG
Saxelin, M., Elo, S., Salminen, S., & Vapaatalo, H. (1991) · Microbial Ecology in Health and Disease · doi:10.3109/08910609109140144 · Cited by 101
Self-citationThe effect of antimicrobial agents on fecal flora of children
Sakata, H., Fujita, K., & Yoshioka, H. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.2.225 · Cited by 69
Lara‐Villoslada, F., Olivares, M. M., & Xaus, J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374938-3.00004-9 · Cited by 36
Mykkänen, Laiho, & Salminen (1998) · Journal of Applied Microbiology · doi:10.1046/j.1365-2672.1998.00454.x · Cited by 26
Cited by
Gut flora in health and disease
Guarner, F., & Malagelada, J.-R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,365
Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens
Servin, A. L. (2004) · FEMS Microbiology Reviews · doi:10.1016/j.femsre.2004.01.003 · Cited by 1,236
Probiotic bacteria: safety, functional and technological properties
Saarela, M., Mogensen, G., Fondén, R., Mättö, J., & Mattila-Sandholm, T. (2000) · Journal of Biotechnology · doi:10.1016/s0168-1656(00)00375-8 · Cited by 1,202
Probiotics, Prebiotics, and Synbiotics
de Vrese, M., & Schrezenmeir, J. (2008) · Advances in Biochemical Engineering/Biotechnology · doi:10.1007/10_2008_097 · Cited by 1,028
McFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872
Metadata
- Authors
- Arvola, T., Laiho, K., Torkkeli, S., Mykkänen, H., Salminen, S., Maunula, L., & Isolauri, E.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 1999-11-01
- Volume
- 104
- Issue
- 5
- Pages
- e64-e64
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2127805721
- Cited by
- 427
- References
- 19
- FWCI
- 39.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.